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Suppressor of cytokine signaling (SOCS) proteins
play a pivotal role in the development and progres-
sion of various cancers. We have previously shown
that SOCS-3 is expressed in prostate cancer, and its
expression is inversely correlated with activation of
signal transducer and activator of transcription factor
3. We hypothesized that SOCS-1, if expressed in pros-
tate cancer cells, has a growth-regulatory role in this
malignancy. The presence of both SOCS-1 mRNA and
protein was detected in all tested cell lines. To assess
SOCS-1 expression levels in vivo , we analyzed tissue
microarrays and found a high percentage of positive
cells in both prostate intraepithelial neoplasias and
cancers. SOCS-1 expression levels decreased in sam-
ples taken from patients undergoing hormonal ther-
apy but increased in specimens from patients who
failed therapy. In LNCaP-interleukin-6 prostate can-
cer cells, SOCS-1 was up-regulated by interleukin-6
and in PC3-AR cells by androgens; such up-regulation
was also found to significantly impair cell prolifera-
tion. To corroborate these findings, we used a specific
small interfering RNA against SOCS-1 and blocked
expression of the protein. Down-regulation of SOCS-1
expression caused a potent growth stimulation of
PC3, DU-145, and LNCaP-interleukin-6 cells that was
associated with the increased expression levels of
cyclins D1 and E as well as cyclin-dependent kinases
2 and 4. In summary, we show that SOCS-1 is ex-
pressed in prostate cancer both in vitro and in vivo
and acts as a negative growth regulator. (Am J Pathol
2009, 174:1921–1930; DOI: 10.2353/ajpath.2009.080751)
Prostate cancer is the second most common cause of
tumor-related deaths in the Western world. Although lo-
calized tumors can be successfully treated with surgery
or radiotherapy, clinically approved therapy for ad-
vanced prostate cancer is limited to androgen ablation,
blockade of the androgen receptor (AR) or chemother-
apy. Recent modest improvements in chemotherapy
have been achieved with the anti-microtubule agent
docetaxel.
Prostate cancer initiation and progression strongly de-
pend on activation of the AR, but chronic inflammation of
the prostate may also play an important role.1 Therefore,
it is not surprising that the role of the proinflammatory
cytokine interleukin-6 (IL-6) in prostate carcinogenesis
has received a considerable interest. IL-6 is a multifunc-
tional cytokine that acts in a cell type-specific manner
through activation of signaling pathways of Janus ki-
nases/signal transducer and activator of transcription
factors (STAT), mitogen-activated protein kinases, and/or
phosphotidylinositol 3-kinase. In prostate cancer cells,
either pro-differentiation or survival effects of IL-6 have
been described.2 The mechanisms responsible for differ-
ential activation of IL-6 signaling pathways in prostate
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tumor cells are being investigated. It is assumed that
various regulators of phosphorylation of STAT3, in partic-
ular suppressors of cytokine signaling (SOCS) and pro-
tein inhibitors of activated STAT, determine activation
status of this transcription factor. The SOCS family com-
prises eight members, SOCS 1 through 7 and CIS.3
SOCS family members share the central Src homology 2
domain and SOCS box in the carboxy-terminal end,
which plays a crucial role in proteasomal degradation of
binding partners. SOCS-1 and -3 contain a kinase inhib-
itory region, which has a pivotal function in antagonizing
activation of Janus kinases.
The role of SOCS-1 and -3 in carcinogenesis is of
interest since it was shown by several groups that their
expression may be altered in head and neck cancer,4,5
gastric carcinoma,6 chronic myeloid leukemia,7 melano-
ma,8 or prostate cancer.9,10 There is an increasing evi-
dence showing that SOCS have different functions de-
pending on the origin of the tumor. Tannapfel and
colleagues have shown that methylation-dependent si-
lencing of the SOCS-1/3 genes in head and neck squa-
mous cell4 and Barretts adenocarcinoma11 is associ-
ated with tumor growth in vitro and in vivo. On the other
hand, it was demonstrated that SOCS-1 is constitutively
expressed in patients with chronic myeloid leukemia 7 or
in human melanoma.8 Our previous studies revealed that
SOCS-3 is increasingly expressed in prostate cancer and
can exert inhibitory effects on induction of apoptosis by
cAMP.9 Other researchers have reported that SOCS-1
can also act as an inhibitor of phosphorylation of STAT3.5
In particular, IL-4 and IL-13 stimulate expression of
SOCS-1 in keratinocytes, which in turn inhibits phosphor-
ylation of STAT3.12 The two cytokines receptors were
detected in prostate cells.13,14 Furthermore, in breast
cancer a N-Myc downstream-regulated gene can induce
SOCS-1, which negatively regulates STAT3 activation.15
Thus, we have asked whether SOCS-1 is expressed in
prostate cancer cell lines and patient samples and what
impact it has on tumor cell proliferation.
In this study, we report that SOCS-1 is expressed at
similar levels in all tested prostate cancer cell lines at
mRNA and protein level. SOCS-1 can be up-regulated by
IL-6 in LNCaP cells. Consistent with the in vitro data, we
have found that SOCS-1 is present in tissue specimens
from prostate cancer patients. Furthermore, using SOCS-
1-regulated expression approach and small interfering
(si)RNA technique, we show a growth-inhibitory effect of
SOCS-1 in three prostate cancer cell lines.
Materials and Methods
Cell Culture and Chemicals
Prostate cancer cells were obtained from American Type
Culture Collection (Rockville, MD). LNCaP sublines
LNCaP-IL-6 and LNCaP-IL-6 were derived during
chronic treatment in the absence or presence of IL-6,
respectively, as described elsewhere.16 LAPC-4 cells
were kindly provided by Dr. Charles Sawyers (University
of California, Los Angeles, CA) and PC3-AR cells were
donated by Dr. Andrew Cato (Research Center Karlsruhe,
Germany). Lipofectamine2000 (LF2000) was purchased
from Invitrogen (Carlsbad, CA) and doxycycline from Sig-
ma-Aldrich (St. Louis, MO). The synthetic androgen
methyltrienolone (R1881) is a product of DuPont NEN
(Boston, MA) and IL-6 was purchased from R&D (Minne-
apolis, MN).
Quantitative Real-Time PCR
Quantitative real-time PCR was performed as previously
published.9 The primer/probe sequences for SOCS-1
were as follows: forward primer: 5-TTTTCGCCCTTAGCGT-
GAAG-3; reverse primer: 5-CATCCAGGTGAAAGCGGC-
3; Taqman-probe: FAM-5-CCTCGGGACCCACGAG-
CATCC-3-TAMRA.17 TATA-Box binding protein was used
as a housekeeping gene.18
Western Blot
Western blotting analysis, including harvesting and cell
lysis, was performed as previously reported.9 The ex-
pression of SOCS-1 was investigated after culturing the
cells in charcoal-stripped fetal calf serum with increasing
concentrations of androgen as described for SOCS-3.10
The following antibodies were used: rabbit anti-human
SOCS-1 antibody (Acris Antibodies, Hiddenhausen, Ger-
many), mouse anti-human glyceraldehyde 3-phosphate
dehydrogenase (Chemicon International, Temecula,
Figure 1. SOCS-1 mRNA and protein levels in
prostate cancer cell lines. Cells were grown un-
der standard conditions and SOCS-1 expression
levels were measured using quantitative real-
time PCR and Western blot, respectively.
SOCS-1 mRNA levels were normalized to levels
of the housekeeping gene encoding TATA-box
binding protein and those of SOCS-1 protein to
the value of -actin. Data represent mean
value  SE; n  4 independent experiments
carried out in triplicate.
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Figure 2. Expression of SOCS-1 and Ki-67 in normal prostate tissue, PIN (prostate intraepithelial neoplasia) and carcinoma obtained from individuals before or
after androgen-deprivation therapy (ADT). A: SOCS-1 immunoreactivity in samples from patients with prostate cancer and (B) SOCS-1 staining in human prostate
cancer from a patient who failed endocrine therapy. Immunohistochemistry for SOCS-1 was performed using the ABC staining kit according to the manufacturer’s
recommendations. SOCS-1 expression levels were analyzed quantitatively using a single cell resolution technique with the HistoQuest software. C: Percentage
of Ki-67-positive cells in untreated, treated, and therapy-resistant prostate cancer and adjacent PIN and normal tissue. Data represent mean  SE. D: Ki-67 staining
in representative samples of human prostate cancer, adjacent PIN, and normal tissue.
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CA), mouse anti-human -actin (Chemicon), mouse anti-c-
Myc and anti-cyclin E (Santa Cruz Biotechnology, Santa
Cruz, CA), mouse anti-cyclin-dependent kinase (cdk 2) and
cdk 4 (Biosource International, Camarillo, CA), and rabbit
anti-cyclin D1 (LabVision Neomarkers, Fremont, CA).
Patient Samples
We established tissue microarrays using samples from
prostate cancer patients (mean age 62, age range 47 to
73) comparing normal, prostate intraepithelial neoplasia
(PIN), and high- and low grade cancer areas. To com-
pare the expression levels of proteins of interest from
patients without prostate cancer, normal prostate tissue
from patients who underwent cystectomy was included.
We introduced four tissue arrays of eight patients with
prostate cancer before, and eight patients after androgen
ablation therapy. Tumor grade and stage were deter-
mined independently by two pathologists (M.S., L.K.).
Four patients whose samples were obtained before ther-
apy presented with Gleason score 7, two with Gleason 6,
and one with Gleason 9 and 5, respectively. All those
patients had tumor stage pT2c, whereas patients who
received therapy presented with tumor stage 3a (three
cases), 4a (two cases), and either 2a, 2b, or 3b (one case
each). Samples from five patients with therapy-resistant
tumors were also used. Target gene expression analysis
was performed using immunofluorescence microscopy
and our digital image techniques. The procedure con-
cerning patients data protection was according to reg-
ulations of Medical University of Vienna.
Immunohistochemistry
For histological analysis and immunohistochemistry, tu-
mors were fixed with neutral buffered 4% paraformalde-
hyde. The tissues were then embedded in paraffin. The
sections (5 m) were stained either with hematoxylin and
eosin or processed further. Immunohistochemistry stain-
ing for SOCS-1 (H93 antibody, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and Ki-67 (MIB-1 antibody, DAKO,
Glostrup, Denmark) was performed using the ABC kit
(Vector Laboratories, Burlingame, CA) according to the
manufacturers recommendations. As a negative control,
staining was performed on selected sections without the
primary antibodies.
Image Acquisition and Protein Quantification in
Vivo
Samples were analyzed with a Zeiss AxioImager Z1 micro-
scope system with CCD camera and an automated acqui-
sition system (TissueGnostics, Vienna, Austria).19,20 The
percentage of SOCS-1- and Ki-67-positive cells was deter-
mined. Pictures were acquired using Aquest software. Sta-
tistics flow analysis was done with software WinMDI.
Plasmid and Short Interfering RNA
Transfections
PC3, DU-145, and LNCaP-IL-6 cells were seeded onto
six-well plates and transfected with either expression
vector or siRNA using Lipofectamine2000 according to
the manufacturers protocol. For SOCS-1 overexpres-
sion, PC3 and DU-145 clones transfected with 1 g of the
pBig2i plasmid per well containing a tetracycline-regu-
lated tricistronic transactivator/repressor and the tetracy-
cline-responsive cMyc-tagged SOCS-1. Medium was
changed 8 hours later and doxycycline (2 g/ml) was
added. cMyc-tagged-SOCS-1 expression levels were
measured 48 and 72 hours after transfection. For 3H-
thymidine incorporation assay, the conditions were
adapted to 96-well plates and proliferation was measured
48 hours after transfection.
For siRNA experiments, we have used the modified
RNAi protocol supplied by Invitrogen with siRNA concen-
trations between 10 and 100 nmol/L. The following siRNA
Figure 3. Regulation of expression of SOCS-1 by androgen in (A) PC3-AR, (B) LNCaP-IL-6 and (C) parental LNCaP ATCC cells. The cells were treated with
increasing concentrations of the synthetic androgen methyltrienolone (R1881) for 72 hours and SOCS-1 levels were determined by Western blot. The results are
representative of three independent experiments.
Table 1. Percentage of SOCS-1-Positive Cells in Normal Prostate Tissue, PIN, and Cancer Tissue Obtained from Patients with
Untreated, Treated, and Therapy-Resistant Cancer
Untreated patients Patients treated with ADT Patients with therapy-resistant cancer
Normal tissue 37.82 44.3 33.22
PIN 90.26 85.16 n.d.
Cancer tissue 90.02 66.27 82.65
n.d., not determined.
PIN, prostate intraepithelial neoplasia.
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sequences were previously published21: SOCS-1 sense
strand: 5-GCAUCCGCGUGCACUUUCAUU-3; SOCS-1
antisense strand: 5-AAUGAAAGUGCACGCGGAUGC-
3; -Galactosidase sense strand: 5-UUAUGCCGA-
UCGCGUCACAUU-3; -Galactosidase antisense
strand: 5-AAUGUGACGCGAUCGGCAUAA-3. Mock-
transfected cells were grown in the presence of Lipo-
fectamine only. mRNA levels were read 48 hours after
transfection, whereas protein levels were measured 72
hours later. For long-term experiments, the following pro-
tocol was applied: the cells were seeded on day one, the
first transfection was carried out on the next day and
medium was changed on day three followed by a 48
hours incubation period. Then the second transfection
was performed with the subsequent change of medium
24 hours later and additional incubation for 48 hours.
3H-thymidine incorporation was measured 72 and 144
hours after siRNA treatment.
Statistical Analysis
The following procedure was carried out to test signifi-
cance of findings: all treatment and control groups were
tested for Gaussian distribution using Kolmogorov-Smir-
nov-Test. As non-Gaussian distribution was found in all
groups, non-parametric unpaired Kruskal-Wallis test was
applied to compare more than two and Mann-Whitney-U-
test was used to compare two groups. All P values were
corrected according to Bonferroni. P values below 5%
were defined as statistically significant and encoded as
follows: * P  0.05, ** P  0.01, *** P  0.001.
Results
SOCS-1 Expression Is Detected in Prostate
Cancer Cell Lines
To evaluate the expression of SOCS-1 in human prostate
cell lines, we first measured its mRNA by quantitative
real-time PCR and normalized the values according to
those of the housekeeping gene encoding TATA-box
binding protein. We found no significant differences in
mRNA levels between the cell lines. SOCS-1 mRNA lev-
els of DU-145 and PC3 cells were slightly lower (Figure 1,
left panel). Using Western blot technique, however, we
found slightly higher protein levels in DU-145 cells in
comparison with the other cell lines (Figure 1, right
panel). These changes were not statistically significant.
SOCS-1 Expression Is Decreased in Patients
after Androgen Ablation Therapy and Is
Elevated in Recurrent Cancer
To obtain a deeper insight into the regulation of SOCS-1
during carcinogenesis and therapy, we conducted tissue
microarrays using patients samples (Figure 2, see sup-
plementary Figure 1, http://ajp.amjpathol.org and Table
1). In normal tissue, SOCS-1 was mostly detected in the
cytoplasm of basal cells. There was a high percentage of
SOCS-1-positive cells in PIN and carcinoma (normal tis-
sue: 37.82%, PIN: 90.26%, carcinoma: 90.02%) (Figure
2A). To investigate possible changes in SOCS-1 expres-
sion levels during androgen ablation, we also analyzed
samples from patients who received this therapy.
SOCS-1 expression was down-regulated in those sam-
ples. The percentage of SOCS-1-positive cells in carci-
noma decreased to 66% in samples from patients who
underwent therapy. However, the percentage of SOCS-1
in specimens obtained from patients who failed therapy
raised to 82.65% (Figure 2B). To better understand the
relationship between SOCS-1 expression and tumor cell
proliferation in vivo, we performed tissue microarray and
determined the percentage of Ki-67-positive cells (Figure
2, C and D). The Ki-67 index was the highest in therapy-
resistant tumors, followed by levels measured in un-
treated cancer. Low percentages of Ki-67-positive cells
were detected in tumor tissue during androgen with-
drawal therapy similar to the level seen in normal tissue.
On the basis of these in vivo results, we hypothesized that
Figure 4. IL-6 induces SOCS-1 protein but not mRNA in LNCaP-IL-6 cells
and inhibits cellular growth. Cells were seeded onto six-well plates and
treated with 10 ng/ml of IL-6 for the indicated time periods. RNA was isolated
and transcribed into cDNA or whole cell lysates were prepared. Graphs show
levels of SOCS-1 mRNA (top) and protein (middle), respectively. Inhibition
of proliferation by IL-6 is also shown (bottom); n  3 independent exper-
iments carried out in triplicate. *P  0.05.
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SOCS-1 expression in prostate cancer cells is regulated
by androgen. This hypothesis was tested in PC3 cells
stably transfected with the AR cDNA (PC3-AR), parental
LNCaP, and LNCaP IL-6 cells. As shown in Figure 3A,
the treatment of PC3-AR cells with increasing concentra-
tions of R1881 yielded a higher expression of the SOCS-1
protein. However, up-regulation of SOCS-1 in prostate
cancer cells seems to be cell type-specific. In LNCaP
cells and in their derivative LNCaP-IL-6 (Figure 3, B and
C), the levels of SOCS-1 did not change after androgen
treatment. Taken together, our results suggested that
alterations in expression of SOCS-1 in tissue specimens
obtained from prostate cancer patients are context
dependent.
SOCS-1 Is Up-Regulated by IL-6 in LNCaP
Cells and Inhibits Proliferation
To elucidate the influence of IL-6 on SOCS-1 expression,
we treated LNCaP cells with IL-6 (10 ng/ml). Using quan-
titative real-time PCR we found no significant alteration of
SOCS-1 mRNA levels (Figure 4, top). However, at the
protein level, a significant increase of SOCS-1 already
occurred after 15 to 30 minutes of treatment, although
followed by a rapid decline to almost basal levels after 60
minutes (Figure 4, middle). Whether the transient in-
crease of SOCS-1 protein could be a result of reduction in
the rate of degradation remains to be determined. This
effect was functionally associated with a significant inhi-
bition of proliferation (Figure 4, bottom). PC3 and DU-145
cells were also tested under the same conditions. How-
ever, because of the presence of endogenous autocrine
IL-6 loop, these cells apparently did not further respond
to exogenous IL-6 either by the effect on SOCS-1 levels
or on proliferation (data not shown).
Up-Regulation of SOCS-1 in Prostate Cancer
Cells Causes Growth Inhibition
To directly examine the effect of SOCS-1 on growth of
androgen-insensitive prostate cancer cells, we trans-
fected these cells with a tetracycline-responsive SOCS-1
expression plasmid. Doxycycline enhanced SOCS-1 ex-
pression with the maximal effect seen after 48 hours. The
induction was eight- and 16-fold in PC3 and DU-145
cells, respectively (Figure 5A). Under those conditions,
proliferation, as assessed by the 3H-thymidine incorpo-
ration assay, was significantly reduced by 25% in both
cell lines (Figure 5B). In control experiments, doxycycline
did not induce any effect on proliferation of prostate
cancer cells DU-145 and PC3, which were similarly trans-
fected with the empty vector (supplementary Figure 2,
see http://ajp.amjpathol.org).
Down-Regulation of SOCS-1 Stimulates Cellular
Growth through Effect on Expression of cdk and
Cyclins
To corroborate our above findings, we used siRNA
against SOCS-1 that was published by Zitzmann and
associates.21 SOCS-1 mRNA and protein levels were
lowered to approximately 50% after 72 hours. We as-
sessed cellular proliferation by 3H-thymidine uptake and
found a significant up-regulation in PC3 and DU-145 cells
(Figure 6). A stronger down-regulation of SOCS-1 protein
was achieved by transfection performed at two consec-
utive time points. The levels of SOCS-1 decreased to 20
and 40% in DU-145 and PC3 cells, respectively. In sup-
port of our results reported above, cellular growth was
markedly stimulated in PC3 and DU-145 cells (Figure 7).
To understand the mechanism underlying growth inhibi-
tion of prostate cancer cells by SOCS-1, we measured
expression levels of cyclins and cdk that regulate G1 to S
phase progression of the cell cycle. DU-145 and PC3
(Figure 8, A and B) cells were treated with increasing
concentrations of either SOCS-1 or control siRNA (50 to
100 nmol/L). Following siRNA treatment, there was an
increase in expression of cyclins D1 and E as well as cdk
2 and 4 in DU-145 cells. With the exception of cyclin D1,
these cell cycle regulators were also up-regulated in PC3
cells. Taken together, these data are in concordance with
the results obtained in our proliferation assays. To test
Figure 5. A: Up-regulation of SOCS-1 expression by transient transfection. PC3 and DU-145 cells were seeded onto six-well plates and transfected after 24 hours
with a tetracycline-responsive SOCS-1 expression vector. Protein levels of SOCS-1 were measured 48 and 72 hours later. Controls included the cells grown in
vehicle (PBS) only; n 5 independent experiments carried out in duplicate. B: SOCS-1 overexpression leads to a reduced 3H-thymidine uptake. Cells were seeded
onto 96-well plates and transfected with the pBig2i plasmid. Vehicle or doxycycline (2 g/ml) were supplemented and 3H-thymidine was added after 48 hours.
The assay was analyzed 24 hours later; n  4 independent experiments carried out in triplicate. *P  0.05, **P  0.01.
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whether SOCS-1 knock-down affects growth of AR-posi-
tive cells in the same way as in androgen-insensitive
ones, we repeated siRNA experiments in LNCaP-IL-6
cells. Growth stimulation in that cell line observed after
SOCS-1 siRNA treatment was higher than fivefold (Figure
9). Interestingly, inhibition of proliferation of LNCaP-IL-6
cells by IL-6, which was reported previously was also
observed after down-regulation of SOCS-1.16
Discussion
The important role of SOCS-3 was recently demonstrated
in prostate cancer cells in which STAT3 is not phosphor-
ylated and in tissue specimens obtained from patients.9
SOCS-3 is induced not only by IL-6, but also by andro-
gens and cAMP and acts as a negative feedback regu-
lator of cellular events induced by hormones.9,10 Expres-
sion levels and/or functional significance of SOCS-1 and
-3 were investigated in some premalignant conditions
and malignant tumors. In Barrets adenocarcinoma, they
exhibit a similar pattern of expression.11 However, recip-
rocal expression of SOCS-1 and -3 is associated with
resistance to radiation therapy in human glioblastoma
multiforme cell lines.22 Those authors reported an in-
Figure 6. Inhibition of SOCS-1 expression causes a moderate growth ad-
vantage. Cells (DU-145 and PC3) were seeded onto six- and 96-well plates for
quantitative real-time PCR, Western blot or proliferation assays, respectively.
72 hours after mock or siRNA transfection (final concentration 100 nmol/L),
SOCS-1 levels (top, middle) and proliferation status (bottom) were mea-
sured; n 3 to 5 independent experiments carried out in triplicate. *P 0.05,
**P  0.01.
Figure 7. Long-term knock-down of SOCS-1 causes a strong stimulation of
proliferation. Cells were seeded onto six- and 96-well plates for Western blot
and 3H-thymidine uptake measurement, respectively. Increasing concentra-
tions of siRNA were transfected at two consecutive time points; n  6
independent experiments carried out in triplicate; siRNA concentration is
given 1 nmoL/L. *P  0.05, **P  0.01.
Figure 8. Inhibition of SOCS-1 expression by siRNA leads to elevation of
intracellular levels of cyclins D1 and E and cdk 2 and 4 as determined by
Western blot. Experimental conditions for DU-145 (A, 3 to 4 independent
experiments) and PC3 cells (B, 2 to 4 independent experiments) were the
same as those described in the legend for Figure 7. Data represent mean
value  SE. *P  0.05, **P  0.01.
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creased expression of SOCS-3 and down-regulation of
SOCS-1 levels in glioblastoma cells. Re-expression of
SOCS-1 and inhibition of SOCS-3 yielded increased sen-
sitivity to radiation. Therefore, we asked whether SOCS-1
levels are altered in prostate cancer cell lines and inves-
tigated the functional significance of SOCS-1 expression.
We also hypothesized that SOCS-1 expression inversely
correlates with phosphorylation of STAT3. We determined
the levels of SOCS-1 mRNA and protein in six prostate
cancer cell lines that showed differences in STAT3 phos-
phorylation.9 However, all cell lines have similar levels of
both SOCS-1 mRNA and protein. Our results do not es-
tablish a correlation between activation of STAT3 and
SOCS-1 expression. It is possible that SOCS-1 inhibits
phosphorylation of other STAT factors, such as STAT5
and 6, in selected human prostate cancer cell lines.23,24
IL-6, whose levels increase during prostate carcino-
genesis, is known to exhibit pleiotropic effects in vitro and
in vivo.25,26 We demonstrated that IL-6 inhibits cellular
proliferation of parental LNCaP cells.16 After chronic
treatment with IL-6, newly generated LNCaP-IL-6 cells
gain a growth advantage and increase activation of the
MAPK pathway.27 As expected, IL-6 induced SOCS-1
expression in cells that respond to the exogenous cyto-
kine is associated with growth inhibition. The effect of IL-6
on up-regulation of SOCS-1 protein but not mRNA may
not be surprising. Recently we demonstrated that andro-
gen induces expression of SOCS-3 protein without an
effect on mRNA.10 This experiment, however, did not
definitively answer the question whether SOCS-1 directly
inhibits proliferation of prostate cancer cells. Thus,
SOCS-1 expression was modulated by two different ap-
proaches, ie, introduction of a doxycycline-responsive
SOCS-1 vector or siRNA, in prostate cancer cell lines.
Consecutive transfections of SOCS-1 siRNA yielded an
inhibition of SOCS-1 expression by up to 80%. The results
of those experiments are consistent in terms of retarda-
tion of in vitro growth by SOCS-1. The growth-inhibitory
effect of SOCS-1 in human prostate cancer cell lines is in
concordance with a recent paper in which the authors
described that the SOCS-1 mimetic peptide Tkip is a
negative growth regulator of DU-145 cells.28 It was dem-
onstrated that the SOCS-1 inhibitory effect is mediated
through negative regulation of STAT3 phosphorylation.
DU-145 cells used in our laboratory and those subjected
to treatment with Tkip differ in the phosphorylation of
STAT3.9 Our results are similar to those of Spiotto and
Chung who did not detect phosphorylated form of STAT3
in DU-145 cells after treatment with IL-6.29 Differences in
data on phosphorylation of STAT3 reported by various
laboratories may be explained by results from a recent
publication of Kreis and associates. Those authors dem-
onstrated that STAT3 activity depends on cell density in
melanoma models.30 The fact that inhibition of expres-
sion of SOCS-1 did not prevent growth inhibition by IL-6
in a LNCaP subline leaves the possibility that other mem-
bers of the SOCS family such as SOCS-3 are more im-
portant for growth regulation by IL-6.
As new clues to the effect on proliferation, we demon-
strate that down-regulation of SOCS-1 by siRNA yields
increased expression of cyclins D1 and E and cdk 2 and
4, which drive cell cycle progression to the S phase.
Inhibition of expression of cyclin D1 by SOCS-1 is in
concordance with the report of Flowers and associates.28
We have extended those previous findings and showed
the effect of SOCS-1 on inhibition of critical cell cycle
regulators in the two cell lines, which either lack phos-
phorylated STAT3 (DU-145) or are STAT3-null (PC3).
Thus, our important new finding is that SOCS-1 can act as
a negative growth regulator independently of its inhibitory
role on the JAK-STAT pathway. Investigations on interfer-
ence of SOCS with other signaling pathways in human
prostate cancer seem to be justified. In this context, it is
worthwhile to mention that another negative regulator of
cytokine signaling, protein inhibitors of activated STAT 3
increases sensitivity of lung cancer cells to chemothera-
peutic agents through inactivation of the phosphotidyli-
nositol 3-kinase/Akt pathway.31 Similarly, multiple nuclear
factor kappa B-regulated pathways are inhibited by
SOCS-3 in pancreatic cells.32
The results from other studies investigating the levels
of SOCS-1 in malignant disease suggest that tumor type-
specific differences exist. Liu and colleagues reported
that the SOCS-1 gene is hypermethylated and conse-
quently silenced in vitro and in vivo.33 On the other hand,
Hatirnaz and associates did not confirm those previous
results.34 A role of SOCS-1 as a tumor suppressor is
evident from experiments with knockout fibroblasts,
which are more sensitive to both spontaneous or onco-
gene-induced transformation.35 In melanomas SOCS-1
represses the expression of matrix metalloproteinase, ba-
sic fibroblast growth factor, and vascular endothelial
growth factor thus contributing to inhibition of invasion
and angiogenesis.36 In future studies it may be deter-
mined how SOCS-1 interacts with various partner pro-
teins in human cancer.
Our tissue microarray data revealed the presence of
SOCS-1 in pre-malignant and malignant lesions in the
prostate. Although the presence of a protein that inhibits
proliferation in cancer cells in patients samples may be
regarded as a contradiction, other possible functions of
SOCS-1 have to be considered. SOCS-1 may regulate
prostate cancer immune response. Shen and associates
showed that SOCS-1 silencing results in enhanced anti-
gen presentation by dendritic cells.37 This finding implies
Figure 9. Inhibition of SOCS-1 expression in LNCaP-IL-6 cells leads to
stimulation of proliferation but does not interfere with IL-6-induced growth
inhibition. The cells were transfected with either SOCS-1 or control siRNA in
the presence or absence of IL-6. Proliferation was measured by 3H-thymidine
incorporation. Data represent mean values  SE from three independent
experiments. ***P  0.001.
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that the presence of SOCS-1 impairs immune response to
a tumor. In this context, it should be kept in mind that
transforming growth factor-, a cytokine that is a potent
growth inhibitor in vitro, is increasingly expressed in pros-
tate cancer in which it has angiogenic and immunosup-
pressive properties.38,39 Implications of enhanced ex-
pression of SOCS-1 in vivo may be better understood in
the future when animal models in which its expression
could be regulated are available.
We also show that SOCS-1 levels decreased in pa-
tients undergoing anti-androgen therapy. Explanations
for these in vivo findings are partly offered by results of
experiments performed in the prostate cancer cell line
PC3-AR. In those cells, there was a concentration-depen-
dent stimulatory effect of androgen on the SOCS-1 pro-
tein. These data are similar to our previous findings show-
ing that SOCS-3 expression in prostate cancer cells is
up-regulated by androgens.10 The effect of androgen is,
however, cell type-specific. Interestingly, androgens re-
pressed the expression of human telomerase reverse
transcriptase and telomerase activity in PC3-AR but not in
LNCaP cells.40 Differential regulation of SOCS-1 in pros-
tate cancer cell lines may be explained by either pres-
ence of AR mutation or insufficient expression of a coac-
tivator, which is critical for SOCS-1 expression. It was for
example documented that PC3 but not DU-145 cells
express the coactivators required for tumor suppressor
ability of AR.41 At present, it could be hypothesized that
SOCS-1 down-regulation affects growth regulation by an-
drogens in prostate cancer. However, limitations with
available in vitro models prevented us to study this regu-
lation further. In PC3-AR cells, androgenic hormones
show a minor inhibitory effect on proliferation (data not
shown) and in LNCaP cells SOCS-1 protein was not
regulated by androgen. Increased expression of SOCS-3
in specimens obtained from patients who did not respond
to endocrine therapy may reflect activation of the AR by
non-steroidal compounds such as proinflammatory cyto-
kines or HER-2/neu.42–45 There may be a mechanism by
which steroids regulate SOCS expression in selected cell
lines. It was demonstrated that estrogenic steroids up-
regulate SOCS-3 in hepatic and breast cancer cells.46,47
SOCS-1 expression did not change in normal tissue or
PIN after therapy compared with that in samples obtained
before endocrine treatment. This finding could be ex-
plained by SOCS-1 expression in the basal cells, which
are androgen-insensitive.
Experiments reported in the present manuscript were
carried out with prostate cancer cell lines that are con-
sidered models for an advanced disease. It has been
proposed that proinflammatory cytokines have a role in
early prostate carcinogenesis.1 For further analysis of the
function of IL and SOCS in chronic inflammation that
may lead to cancer, appropriate models should be
developed.
In conclusion, in the present manuscript we show for
the first time that SOCS-1 is expressed in all tested pros-
tate cancer cell lines and in clinical specimens. It is
up-regulated by IL-6 and inhibits proliferation of prostate
cancer cells. Thus, we have demonstrated a growth-
inhibitory effect of SOCS-1 in prostate cancer through
negative regulations of cyclins and cdk. Other possible
aspects of SOCS-1 action in carcinoma of the prostate,
such as regulation of the immune response, should be
addressed in future experimental studies.
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